secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANI PHARMACEUTICALS INC (ANIP)
CIK:        0001023024
Form:       8-K
Filed at:   2024-09-20T23:59:59+00:00
Accession:  0001023024-24-000093
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ANI Pharma closes Alimera Sciences acquisition; $5.50/sh cash plus CVRs
-----------------------------------------------------------------------

- Acquisition closed Sept 16, 2024; Alimera shareholders received $5.50 cash per share plus one CVR per share.
- CVRs tied to net revenue of ILUVIEN and YUTIQ: $140M by FY2026, $160M by FY2027; max payout $0.25 per CVR per milestone.
- Financed with $325M senior secured term loan from JPMorgan-led syndicate plus available cash.
- Pro forma results show combined net loss of $3.4M for H1 2024 and $51.6M for FY2023.
- Audited Alimera financials and unaudited pro forma combined statements filed as Exhibits 99.1-99.3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1023024/000102302424000093/0001023024-24-000093-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1023024/000102302424000093/ani-20240916.htm
  HTML page:      https://secwatch.observer/filing/0001023024-24-000093

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer